Literature DB >> 36117922

Status of glycemic excursions and hypoglycemia in patients with type 1 diabetes 2 months after first initiation of intermittently scanned continuous glucose monitoring: a pilot study.

Yuka Suganuma1, Hiroshi Takahashi1, Rimei Nishimura1.   

Abstract

Objective: To investigate glycemic excursions and changes in time in hypoglycemia (hyT) in Japanese type 1 diabetes (T1D) patients 2 months after the first initiation of intermittently scanned continuous glucose monitoring (isCGM).
Methods: We enrolled 15 adult T1D patients on insulin therapy to evaluate changes in the parameters for glycemic excursions 2 months after initiating isCGM by using the Wilcoxon signed-rank test. Binomial logistic regression analyses were also used to identify predictors of hypoglycemia.
Results: A total of 14 patients were available for analysis. Median HbA1c decreased significantly from 7.6% (interquartile range, 6.9-8.3%) to 7.2% (6.7-7.8%) (P = 0.047). Mean glucose, standard deviation of glucose, time in range, and time above range were not significantly different from baseline, while time below range (from 2.2 [1.0-6.9] to 5.0 [2.0-10.8]%; P = 0.016), hyT (from 26.8 [14.5-75.5] to 56.8 [21.7-110.9] min/day; P = 0.030), and time in severe hypoglycemia (shT, from 4.3 [0.0-8.9] to 11.0 [0.0-24.3] min/day; P = 0.022) increased significantly. Additionally, shT increased significantly only during daytime. The factor associated with hyT was found to be the reduction in total insulin dose after 2 months. Conclusions: In T1D patients with a median HbA1c of 7.6%, HbA1c was significantly decreased 2 months after initiating isCGM, while hyT increased, particularly during daytime. Study results suggest that a reduction in the total insulin dose of about 0.10 U/kg may be required in some cases. These findings need to be taken into account when initiating isCGM. Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-022-00585-y. © The Japan Diabetes Society 2022.

Entities:  

Keywords:  Time below range; Time in hypoglycemia; Time in severe hypoglycemia; Type 1 diabetes; isCGM

Year:  2022        PMID: 36117922      PMCID: PMC9477991          DOI: 10.1007/s13340-022-00585-y

Source DB:  PubMed          Journal:  Diabetol Int        ISSN: 2190-1678


  13 in total

1.  Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.

Authors:  Jan Bolinder; Ramiro Antuna; Petronella Geelhoed-Duijvestijn; Jens Kröger; Raimund Weitgasser
Journal:  Lancet       Date:  2016-09-12       Impact factor: 79.321

2.  Flash Glucose Monitoring is associated with improved glycaemic control but use is largely limited to more affluent people in a UK diabetes centre.

Authors:  J A McKnight; F W Gibb
Journal:  Diabet Med       Date:  2017-05       Impact factor: 4.359

3.  Maturation of CGM and Glycemic Measurements Beyond HbA1c-A Turning Point in Research and Clinical Decisions.

Authors:  Matthew C Riddle; Hertzel C Gerstein; William T Cefalu
Journal:  Diabetes Care       Date:  2017-12       Impact factor: 19.112

4.  Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.

Authors:  Lutz Heinemann; Guido Freckmann; Dominic Ehrmann; Gabriele Faber-Heinemann; Stefania Guerra; Delia Waldenmaier; Norbert Hermanns
Journal:  Lancet       Date:  2018-02-16       Impact factor: 79.321

5.  Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study.

Authors:  Craig J Currie; John R Peters; Aodán Tynan; Marc Evans; Robert J Heine; Oswaldo L Bracco; Tony Zagar; Chris D Poole
Journal:  Lancet       Date:  2010-01-26       Impact factor: 79.321

6.  Evaluation of subcutaneous glucose monitoring systems under routine environmental conditions in patients with type 1 diabetes.

Authors:  Felix Aberer; Martin Hajnsek; Markus Rumpler; Sabine Zenz; Petra M Baumann; Hesham Elsayed; Adelheid Puffing; Gerlies Treiber; Thomas R Pieber; Harald Sourij; Julia K Mader
Journal:  Diabetes Obes Metab       Date:  2017-03-16       Impact factor: 6.577

7.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

8.  Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes.

Authors:  Thomas Haak; Hélène Hanaire; Ramzi Ajjan; Norbert Hermanns; Jean-Pierre Riveline; Gerry Rayman
Journal:  Diabetes Ther       Date:  2017-04-11       Impact factor: 2.945

9.  A Clinical Trial of the Accuracy and Treatment Experience of the Flash Glucose Monitor FreeStyle Libre in Adults with Type 1 Diabetes.

Authors:  Arndís F Ólafsdóttir; Stig Attvall; Ulrika Sandgren; Sofia Dahlqvist; Aldina Pivodic; Stanko Skrtic; Elvar Theodorsson; Marcus Lind
Journal:  Diabetes Technol Ther       Date:  2017-03-06       Impact factor: 6.118

10.  Effect of the FreeStyle Libre™ flash glucose monitoring system on glycemic control in individuals with type 2 diabetes treated with basal-bolus insulin therapy: An open label, prospective, multicenter trial in Japan.

Authors:  Wataru Ogawa; Yushi Hirota; Takeshi Osonoi; Takahiro Tosaki; Yoshiro Kato; Kazunori Utsunomiya; Rimei Nishimura; Jiro Nakamura
Journal:  J Diabetes Investig       Date:  2020-09-09       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.